| BRIDGEBIO PHARMA DL-,001 |
| USA |
| Gesundheit |
| US10806X1028 / A2PLX7 |
| 2CL (Frankfurt) / BBIO (NASDAQ) |
| FRA:2CL, ETR:2CL, 2CL:GR, NASDAQ:BBIO |
| - |
| https://bridgebio.com/ |
|
BridgeBio Pharma is a biopharmaceutical company that discovers, develops, and delivers transformative medicines for patients with genetic diseases and cancers with clear genetic drivers. The company operates through a distinctive decentralized hub-an..
>Volltext.. |
| 12503.6 Mio. EUR |
| 14333.93 Mio. EUR |
| 434.96 Mio. EUR |
| -430.24 Mio. EUR |
| -628.02 Mio. EUR |
| -3.28 EUR |
| 2363.93 Mio. EUR |
| 494.38 Mio. EUR |
| -386.3 Mio. EUR |
| 2.04 |
| 99.43% |
| -19.26% |
| - |
| - |
| - |
| 3 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 10.336.682 USD. |
| BRIDGEBIO |
| 05.04.26 |
|